Assertio Holdings, INC 8-K filings

Assertio Holdings has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement, resolving a previous listing concern.

Assertio Holdings reported its fourth quarter and full year 2023 results, highlighting the impact of the Rolvedon acquisition and generic competition for Indocin, while providing 2024 financial guidance.

Assertio Holdings reported a decrease in net product sales for the fourth quarter of 2023, alongside the appointment of a new board member and the release of 2024 financial guidance.

Assertio Holdings has received a notice from Nasdaq regarding potential delisting due to its stock price falling below $1.00 for 30 consecutive days.

Assertio Holdings' CEO, Daniel A. Peisert, has resigned from his position and the board, effective immediately, following the execution of a waiver and release agreement.